Immunosuppressive regimens and skin cancer risk in solid-organ transplant recipients
mTORi-based regimens, particularly with reduced-dose tacrolimus, appear to offer a safer and more effective alternative to CNI-heavy regimens for skin cancer prevention in SOTRs. Real-life data support the integration of mTORis into IS strategies to reduce skin cancer risk, particularly for high-risk patients and those who developed skin malignancies. An author video to accompany this article is available online.
Authors
- Carlos González‐Cruz (ORCID: https://orcid.org/0000-0003-0117-8858)
- Vicente García‐Patos (ORCID: https://orcid.org/0000-0003-1654-6035)
- Álvaro Gómez‐Tomás (ORCID: https://orcid.org/0000-0002-9388-5623)
- Carla Ferrándiz‐Pulido (ORCID: https://orcid.org/0000-0003-3688-9596)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1093/bjd/ljaf483
- Citations
- 2
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71